FDA's No. 2 oncology official departs for biotech startup
A quiet, San Diego-based startup with hundreds of millions to work with just poached the second in command at FDA’s Oncology Center of Excellence — Julia Beaver.
Beaver, who spent almost 10 years at FDA, was most recently the acting deputy director of the Office of Oncologic Diseases, one step on the career ladder below FDA’s oncology chief Rick Pazdur.
According to her LinkedIn, Beaver has been SVP of clinical development at Treeline Biosciences since January. The biotech, focused on the “outer edge of scientific possibility,” was co-founded by ex-Loxo chief Josh Bilenker, who was a life sciences VC investor in a prior life, and before that, a medical officer at the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
